| BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018 | ||||
| Theme: Rethinking the Next Big Things in Pharma Innovations | ||||
| Time: August 16-19, 2018 Place: Boston Marriott Cambridge, USA |
||||
| Scientific Program | ||||
| Stream 1 | Stream 2 | Stream 3 | Stream 4 | Stream 5 |
| Stream 3: Industrial Art Gallery -Arts in Billion Dollar Molecules and Next Generation Therapy |
Substream 3-1: Improved Linear Drug Discovery on Selected Current Drug Targets Substream 3-6: Clinical Trial Gateway and Translational Convergence |
| Substream 3-1: Improved Linear Drug Discovery on Selected Current Drug Targets |
|||
|
Session 3101: Improved Targeted Drug Discovery Day 1: Afternoon, Thursday, August 16, 2018 Place: Endeavor Room, 3rd Floor 15:25-17:10 |
|||
| Chair: Dr. Scott Hansen, Associate Professor, The Scripps Research Institute, USA | |||
| Time | FaceOn | Speeches and Speakers | |
| 15:25-15:30 | Chair's Introduction | ||
| 15:30-15:50 |  |
Title: Using Ligand Bias to Refine Novel Dopamine D1 Receptor Agonists Dr. John A. Allen, Assistant Professor, Pharmacology and Toxicology, University of Texas Medical Branch; Principal Scientist, Neuroscience Research Unit, Pfizer, Inc., USA |
|
| 15:50-16:10 |  |
Title: Targeting the PIP2 Paradigm of Lipid-gated Ion Channels in HTS Drug Discovery Dr. Scott Hansen, Associate Professor, The Scripps Research Institute, USA |
|
| 16:10-16:30 |  |
Title: New Target to Treat Neurodegenerative Disorders: RNA Binding Protein – mRNA Complex Dr. Maria Maccecchini, Founder & CEO, QR Pharma, Inc., USA |
|
| 16:30-16:50 |  |
Title: Glucagon-like Peptide 2 Prevents Down-regulation of Intestinal Multidrug Resistance-associated Protein 2 Induced by Experimental Endotoxemia Dr. Maite R. Arana, Post-doctoral Fellow, Institute of Experimental Physiology, Argentina |
|
| 16:50-17:10 | \ |
Title: Drug Resistance, An Enemy of Targeted Cancer Therapies Dr. Alan M. Kleinman, Physician, Merced Faculty Associates, USA |
|
|
Session 3102: Biomarkers, Personalized Medicine and Pharmacogenomics Day 2: Afternoon, Friday, August 17, 2018 Place: Enterprise Room, 3rd Floor 13:30-15:15 |
|||
| Chair: Dr. Shanrong Zhao, Director, Pfizer Worldwide Research and Development, USA | |||
| Time | FaceOn | Speeches and Speakers | |
| 13:30-13:35 | Chair's Introduction | ||
| 13:35-13:55 |  |
Title: Identify Genes Implicated in Kidney Disease Pathogenesis by Comprehensive RNA-seq Data Analysis
Dr. Shanrong Zhao, Director, Pfizer Worldwide Research and Development, USA |
|
| 13:55-14:15 |  |
Title: Multi-omics Based Data Driven Protocols for Biomarker Discovery and Complementary Diagnostic Development Dr. Vladimir Tolstikov, Director, BERG LLC,USA |
|
| 14:15-14:35 |  |
Title: Identification of a Predictive Gene Signature through Machine Learning for Therapeutic Response – A Case Study of Clinical Genomic Data Dr. Hyunjin Shin, Senoir Scientist, Data Science Institute, Takeda Pharmaceuticals, USA
|
|
| 14:35-14:55 |  |
Title: The Biochemistry of Human Flavin-containing Monooxygenase 3 (FMO3) and Its Strict Connection to the TMAO Biomarker Dr. Gianluca Catucci, Assistant Professor, Department of Life Sciences and Systems Biology, University of Turin, Italy |
|
| 14:55-15:15 |  |
Title: Development of Animal Models to Screen the Metabolic Biomarkers in Multiple Sclerosis. Dr. Kouichi Ito, Associate Professor, Rutgers-Robert Wood Johnson Medical School, USA
|
|
| 15:15-15:30 | Coffee Break | ||
© 2003-2018 All rights reserved by BITeomics Inc. |